Compounded Semaglutide:
Is It Safe, Legal, and Worth It?

Compounding is the process of creating a medication tailored to an individual patient's needs. It has a long, legitimate history in pharmacy — before mass manufacturing, all medications were compounded. Today, compounding pharmacies legally produce medications when a prescriber writes a patient-specific prescription.

There are two types of compounding pharmacies, and the distinction matters enormously:

• 503A pharmacies operate under state pharmacy boards. They compound medications based on individual prescriptions for individual patients. They are not required to follow current Good Manufacturing Practices (cGMP), though many voluntarily do. Most compounding pharmacies fall into this category.
• 503B outsourcing facilities are registered with the FDA and must follow cGMP. They can produce compounded medications in larger quantities without patient-specific prescriptions. They undergo regular FDA inspections. These are generally considered the safer option for compounded injectables because of the stricter manufacturing controls.

The FDA's stance on compounded semaglutide has evolved. Here's the current landscape:

• Compounding is legal when a drug is on the FDA shortage list. Semaglutide was on the shortage list from March 2022 through 2024, which allowed compounding pharmacies to legally produce it. When a drug comes off the shortage list, the legal basis for compounding becomes more restricted.
• Compounded semaglutide is not FDA-approved. This means it hasn't gone through the same approval process as Ozempic or Wegovy. It may contain different inactive ingredients, different concentrations, or semaglutide combined with other compounds (like B12 or NAD+).
• The FDA has issued warnings about adverse events associated with compounded semaglutide, including reports of wrong dosing, contamination, and the use of semaglutide salt forms (like semaglutide sodium) that are not bioequivalent to the base form used in brand-name products.
• Novo Nordisk has sued multiple compounding pharmacies and telehealth companies, arguing that compounding copies of non-shortage drugs violates their patents. These legal battles are ongoing and may reshape the compounding landscape.

The legal and regulatory situation is fluid. What's legal today may change. Check the FDA's drug shortage database for the current status of semaglutide before making decisions based on shortage-related compounding allowances.

Compounded injectables carry risks that oral compounded medications do not. Anything injected into your body must be sterile, accurately dosed, and free of contaminants. Here are the specific concerns:

• Sterility failures: Injectable medications require aseptic manufacturing conditions. A 503B outsourcing facility is required to meet these standards and is inspected by the FDA. A 503A pharmacy may or may not have the same level of sterility controls, depending on state regulations and the individual pharmacy's practices.
• Dosing accuracy: Brand-name semaglutide is delivered in pre-filled pens with precise dosing mechanisms. Compounded semaglutide typically comes in multi-dose vials that require the patient to draw up their own dose using a syringe. Measurement errors are possible, especially at the very small volumes used for lower doses.
• Semaglutide salt forms: Some compounding pharmacies have used semaglutide sodium instead of semaglutide base. These are not bioequivalent — the sodium salt has a different molecular weight, meaning that "5 mg of semaglutide sodium" contains less active semaglutide than "5 mg of semaglutide base." This can lead to under-dosing.
• Added ingredients: Many compounded formulations include additional ingredients like vitamin B12, L-carnitine, or NAD+. While these additions are generally safe, they haven't been studied in combination with semaglutide, and they add complexity to an injectable product.
• Storage and shipping: Semaglutide requires refrigeration. Compounded products shipped through the mail must maintain cold chain integrity. Not all providers handle this correctly.

Cost is the primary driver behind the compounding market. Here's what you're actually looking at in early 2026:

• Wegovy (brand semaglutide for weight loss): ~$1,300/month list price. With insurance: $0–$50/month with manufacturer savings card. Without insurance: $1,300+.
• Ozempic (brand semaglutide for diabetes): ~$900–$1,000/month list price. Insurance coverage depends on diabetes diagnosis.
• Compounded semaglutide (503B facility): $200–$400/month, depending on dose, provider, and whether additional ingredients are included.
• Compounded semaglutide (503A pharmacy): $150–$300/month. Generally cheaper than 503B due to lower overhead, but with fewer manufacturing safeguards.
• Telehealth-prescribed compounded: $150–$500/month including prescriber visit fees. Many bundle the prescriber consultation with the medication cost.

Several telehealth platforms have built businesses around prescribing compounded GLP-1 medications. Here's an overview of the major players as of late 2025:

• Mochi Health: Offers compounded semaglutide and tirzepatide. Includes prescriber visits, lab monitoring, and coaching. Pricing varies by state and medication.
• Sequence (now WeightWatchers Clinic): Was one of the first telehealth platforms for GLP-1 prescriptions. Offers both brand-name and compounded options depending on insurance status.
• Found: Focuses on weight management with both GLP-1 and non-GLP-1 medication options. Offers compounded semaglutide through partner pharmacies.
• Hims & Hers: Entered the GLP-1 market with compounded semaglutide at aggressive pricing. Uses 503B outsourcing facilities for their compounded products.
• Ro (Roman/Rory): Offers compounded GLP-1 options alongside their broader telehealth platform.

None of these platforms are inherently better or worse than getting a prescription from your primary care doctor. The quality depends on the compounding pharmacy they partner with, the thoroughness of their medical screening, and whether they provide ongoing monitoring.

If you decide to use compounded semaglutide, do your due diligence:

• Check FDA registration: 503B outsourcing facilities are listed on the FDA website. Search the FDA's "Registered Outsourcing Facilities" page to verify.
• Verify state licensing: All compounding pharmacies must be licensed by their state board of pharmacy. You can verify this on your state board's website.
• Look for PCAB accreditation: The Pharmacy Compounding Accreditation Board (PCAB) accredits compounding pharmacies that meet quality standards. Accreditation is voluntary but signals a commitment to quality.
• Ask about testing: Reputable pharmacies perform third-party testing for potency, sterility, and endotoxin levels on their compounded products. Ask for certificates of analysis.
• Ask about the semaglutide form: Specifically ask whether they use semaglutide base or semaglutide sodium, and whether their dosing accounts for any molecular weight differences.
• Check the beyond-use date: Compounded medications have shorter shelf lives than manufactured drugs. A compounded semaglutide vial typically has a beyond-use date of 30–90 days.

Walk away from any provider or pharmacy that:

• Sells semaglutide without requiring a prescription from a licensed prescriber
• Doesn't require any medical screening, lab work, or health history
• Ships medications without temperature-controlled packaging
• Can't tell you whether they're a 503A or 503B facility
• Offers prices that seem too good to be true (under $100/month should raise questions)
• Markets the product as "Ozempic" or "Wegovy" — compounded semaglutide is a different product
• Won't provide a certificate of analysis or third-party testing results
• Requires you to buy months of supply upfront with no refund policy
• Uses aggressive social media marketing with before/after photos and no medical disclaimers

There's no universal answer. Here's a framework:

Compounded may be reasonable if:

• You don't have insurance coverage for brand-name GLP-1 medications
• You've verified the pharmacy is a 503B outsourcing facility with FDA registration
• Your prescriber is willing to monitor your progress and adjust doses
• You understand and accept the risks of a non-FDA-approved product
• You're committed to tracking your response (since compounded products may have different bioavailability)

Stick with brand-name if:

• Your insurance covers it (check before assuming it doesn't)
• You have risk factors that make dosing precision especially important (e.g., diabetes requiring tight glucose control)
• You're uncomfortable with the risks of non-FDA-approved injectables
• You prefer the convenience and reliability of pre-filled pens

Whatever you choose, tracking your response is essential. Compounded semaglutide may have different bioavailability than brand-name — meaning the same dose number might produce a stronger or weaker effect. Logging your symptoms, weight, and side effects gives you and your prescriber the data to adjust intelligently.